Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2025 | The future of MDT in oligometastatic prostate cancer

Alexander Sherry • 13 Feb 2025
GU Cancers 2025
Genitourinary Cancer Prostate Cancer
ARTO RADIOSA

Alexander Sherry, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the role of metastasis-directed therapy (MDT) in oligometastatic prostate cancer, highlighting the need for further investigation before establishing MDT as the standard of care. While promising results have been shown in various trials, including RADIOSA (NCT03940235) and ARTO (NCT03449719), the optimal approach, including combination with ADT or other agents, remains an area of active study. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alexander Sherry

What remaining unmet needs are there in oligometastatic prostate cancer?
1:26
What remaining unmet needs are there in oligometastatic prostate cancer?
Alexander Sherry • 13 Feb 2025
EXTEND: Phase II trial of MDT plus ADT in oligometastatic prostate cancer
3:32
EXTEND: Phase II trial of MDT plus ADT in oligometastatic prostate cancer
Alexander Sherry • 13 Feb 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals